Business
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer Topline data from first five patients in proof-of-concept (PoC) human clinical study expected in June Cash runway to fund operations into first calendar quarter of 2025 THE WOODLANDS, TX, May 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reported financial results for the fiscal year 2024 ended March 31, 2024 and provided a corporate update. Recent Highlights Completed its initial public offering (IPO) of common stock. The Company raised gross proceeds of $11.2 million and net proceeds of $9.8 million;Completed site initiation for its PoC human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain;Entered into a clinical site agreement with “АКFА MEDLINE” Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain;Commenced enrollment and announced the safe completion of the first three patient procedures for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain;Appointed Jennifer Cook as Chief Business Officer;Announced successful results from an animal study evaluating the Company’s proprietary catheter-based sensing technology for use in the renal artery;Announced issuance of U.S. patent covering proprietary catheter-based technology for the treatment of cancer related pain;Entered into a service agreement with NoiseFigure Research, Inc. (NFR), a premier application specific integrated circuits (ASICs) service provider to develop next generation of its proprietary microchip; andAnnounced the successful completion of an animal study evaluating the ability of targeted nerve ablation to impact tumor metastases. Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant...